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MaBACKGROUND Although recent observations suggest a favorable initial healing process of the everolimus-eluting
bioresorbable vascular scaffold (BVS), little is known regarding long-term healing response.
OBJECTIVES This study assessed the in vivo vascular healing response using optical coherence tomography (OCT)
5 years after elective ﬁrst-in-man BVS implantation.
METHODS Of the 14 living patients enrolled in the Thoraxcenter Rotterdam cohort of the ABSORB A study, 8 patients
underwent invasive follow-up, including OCT, 5 years after implantation. Advanced OCT image analysis included luminal
morphometry, assessment of the adluminal signal-rich layer separating the lumen from other plaque components, visual
and quantitative tissue characterization, and assessment of side-branch ostia “jailed” at baseline.
RESULTS In all patients, BVS struts were integrated in the vessel and were not discernible. Both minimum and mean
luminal area increased from 2 to 5 years, whereas lumen eccentricity decreased over time. In most patients, plaques were
covered by a signal-rich, low-attenuating layer. Minimum cap thickness over necrotic core was 155  90 mm. One patient
showed plaque progression and discontinuity of this layer. Side-branch ostia were preserved with tissue bridge thinning
that had developed in the place of side-branch struts, creating a neo-carina.
CONCLUSIONS At long-term BVS follow-up, we observed a favorable tissue response, with late luminal enlargement,
side-branch patency, and development of a signal-rich, low-attenuating tissue layer that covered thrombogenic plaque
components. The small size of the study and the observation of a different tissue response in 1 patient warrant judicious
interpretation of our results and conﬁrmation in larger studies. (J Am Coll Cardiol 2014;64:2343–56) © 2014 by the
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ABBR EV I A T I ON S
AND ACRONYMS
BVS = bioresorbable vascular
scaffold(s)
ICC = intraclass correlation
coefﬁcient
IQR = interquartile range
IVUS = intravascular
ultrasound
OCT = optical coherence
tomography
SB = side branch
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2344everolimus-eluting BVS (Absorb BVS 1.0;
Abbott Vascular, Santa Clara, California) was
associated with a good long-term clinical
outcome after 2 and 5 years (2,3). Plaque
regression from 2 to 5 years and recovery of
vasomotion in the scaffolded segment were
documented in a patient subset (4). Moreover,
recent clinical observations of a signal-rich
layer separating potentially thrombogenic
plaque components from the lumen (5,6) sug-
gest a favorable long-term healing response
with potential plaque sealing.SEE PAGE 2357We aimed to provide a comprehensive optical coher-
ence tomography (OCT) analysis of the vascular
healing response in the longest follow-up available to
date (5 years) in the ﬁrst series of patients who
received everolimus-eluting BVS.
METHODS
PATIENT POPULATION. The study population (4)
and index procedure (2) have been described
(Online Appendix). Brieﬂy, all 14 living patients from
the Thoraxcenter Rotterdam cohort of ABSORB A
were asked to participate. Eight consented and were
included. The protocol was approved by the institu-
tional ethics committee and conformed to the Decla-
ration of Helsinki.
OCT IMAGE ACQUISITION. All 8 subjects underwent
frequency-domain OCT at the 5-year invasive follow-
up (7). Six patients at baseline, 7 patients at 6-month
follow-up, and 7 patients at 2-year follow-up had
undergone occlusive time-domain OCT per the study
protocol, with serial OCT imaging at all intervals
available for 5 patients. For details, see the Online
Appendix.
DEFINITIONS. OCT analysis of bioresorbable scaf-
folds reveals essential differences from metal stents
(Figure 1). With metal stents, struts are preserved and
neointimal area is clearly deﬁned as the area between
stent and lumen contour. In BVS, when scaffold struts
are still discernible, the neointimal area can be
assessed similarly to metal stents. However, at long-
term follow-up, BVS scaffold struts are no longer
visible, and the area corresponding to struts and
neointima has similar optical properties as the un-
derlying ﬁbrous layer (5,8). Consequently, it is
impossible to distinguish between strut area, neo-
intimal area, and underlying plaque.
Therefore, the vascular structure observed at
the scaffolded segment, a product of the consoli-
dation of underlying plaque, biodegraded struts,and neointima, resembled a native atherosclerotic
plaque and was deﬁned as neoplaque (Figure 1).
Because OCT cannot distinguish the scaffold area,
and thus neointimal area, from the underlying plaque,
neointimal thickness cannot be assessed directly.
Hence, we aimed to provide an indirect assessment
that focused on the signal-rich layer, which consisted
of the neointimal layer, resorbed struts, and pre-
existing ﬁbrous tissue. We analyzed this signal-rich
layer, between the lumen border and internal elastic
lamina, for providing a measure of separation of the
lumen from underlying plaque components (5,6). In
situations in which signal-poor regions (e.g., calciﬁ-
cations, necrotic core, deeply located ﬁbrous plaque)
obscured delineation of the internal elastic lamina,
the signal-rich layer was delineated between lumen
border and the boundary of signal-rich and signal-
poor regions (Figures 1 and 2).
OCT IMAGE ANALYSIS. The platinum scaffold
markers deﬁned the region of interest. Quantitative
and qualitative 5-year OCT image analysis was per-
formed per frame. Analysis included the assessment
of discernible struts, lumen morphometry, signal-rich
layer thickness measurement, neoplaque character-
ization, attenuation analysis, and ostial side-branch
(SB) assessment. Metal stents implanted in the same
vessels were also analyzed (1).
LUMINAL MEASUREMENTS AND VARIABILITY ANALYSIS.
For details, see the Online Appendix. Measurements
included mean and minimum lumen area and eccen-
tricity, calculated as: ratio (maximum lumen
diameter  minimum lumen diameter)/maximum
lumen diameter (7). Lumen measurements were
assessed for intraobserver, interobserver, and intra-
study variability.
QUANTIFICATION OF SIGNAL-RICH LAYER THICK-
NESS. The signal-rich layer was quantiﬁed following
segmentation of its luminal and abluminal contour
by measuring minimum, mean, and maximum thic-
kness and symmetry (ratio of minimal to maximal
thickness) (Figure 2). Signal-rich layer measurements
were assessed for variability.
NEOPLAQUE CHARACTERIZATION. Neoplaque mor-
phology was assessed per frame at 5 years, according
to native atherosclerosis deﬁnitions (7), and the arc
of calciﬁcations, necrotic core, and mixed plaque
were measured with QCU-CMS (LKEB, Leiden
University, the Netherlands; research version of
QIvus, Medis medical imaging systems, Leiden, the
Netherlands). Fibrous cap contours were traced over
necrotic core with mean and minimum cap thickness
calculated per patient. Spread-out maps represent-
ing neoplaque morphology and cap thickness
FIGURE 1 Long-Term Vascular Healing Response in Metal Stents and
Bioresorbable Scaffolds
After metal stent implantation, struts are preserved and the neointimal area clearly
delineated between stent and lumen contour even at long-term follow-up, with possible
development of neoatherosclerosis within the neointima. Conversely, in long-term follow-
up of bioresorbable scaffolds, neointimal boundaries are unclear after bioresorption
(dotted line), and the intima resembles native plaque, deﬁned as neoplaque. The signal-
rich layer is the layer that separates the underlying plaque components from the lumen.
BVS ¼ bioresorbable vascular scaffold.
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2345throughout the scaffolded segment were generated
(Figure 3) and color-coded by plaque type. The
presence of sharply delineated signal-poor voids,
which corresponded to intimal microchannels (7),
was recorded. In neoplaques with necrotic core, OCT
images were compared with previous follow-ups to
look for de novo accumulation of necrotic core of
adluminal origin, possibly corresponding to
neoatherosclerosis.
ATTENUATION ANALYSIS. We used attenuation
analysis for quantitative tissue characterization of the
signal-rich layer and the neoplaque (Figure 4). In
ex vivo validation experiments, highly attenuating
regions (attenuation coefﬁcient mt $8 mm1) have
been associated with necrotic core or macrophages.
Conversely, mt <6 mm1 were associated with healthy
vessel, intimal thickening, or calciﬁed plaque (9,10).
Attenuation was quantiﬁed circumferentially at
different depths from the lumen surface by custom-
made software (11). Results were plotted in spread-
out maps demonstrating: 1) maximum attenuation
coefﬁcient per A-line throughout the pullback; and 2)
attenuation coefﬁcient values in different depths
from the vessel surface.
SB ASSESSMENT. To assess anatomic SB jailing over
time, 3-dimensional images of SB ostia were obtained
by volume-rendering software (INTAGE Realia, KGT,
Tokyo, Japan) (12). No struts were identiﬁable by
OCT, but neointimal bridges had developed in their
place and were classiﬁed based on their relative
location to the ostium as proximal, distal, proximal
and distal, or crossing (Figure 5). Mean and minimal
thickness was measured in matched frames at
2- and 5-year follow-up with QCU-CMS (Online
Figure 1).
SB ostium area was assessed with dedicated soft-
ware (QAngioOCT 1.0, Medis Specials, Leiden, the
Netherlands). After 3-dimensional reconstruction, a
cut-plane perpendicular to the SB centerline was
selected and SB ostium planimetry performed
(Figure 6) (13).
STATISTICAL ANALYSIS. Continuous variables are
presented as mean  SD or median (interquartile
range [IQR]) and nominal variables as n (%). Signiﬁ-
cance level was set at p < 0.05. Luminal measure-
ments were compared by Wilcoxon signed-rank test.
All other paired comparisons were performed by
paired Student t test. No corrections were made for
multiple comparisons. Variability was assessed with
intraclass correlation coefﬁcients (ICCs) for absolute
agreement and Bland-Altman statistics. Statistical
analysis was performed with SPSS version 20.0 (IBM,
Armonk, New York).RESULTS
LUMEN AND STRUT MEASUREMENTS. No binary
restenosis was witnessed in the 5-year angiograms. In
all patients, scaffold struts were no longer discernible
as a result of complete bioresorption, and lumen area
increased signiﬁcantly from 2 to 5 years (Figure 7).
Lumen eccentricity declined over time (baseline 0.24
 0.13; 6-month follow-up 0.29  0.12; 2-year follow-
up 0.21  0.08; 5-year follow-up 0.15  0.02; p < 0.05
for all comparisons vs. previous studies).
The total strut count was reduced in 5 patients with
serial observations: 278 struts at baseline, 248 at 6
months, 174 at 2 years, and no visible struts at 5 years.
Two cases with incomplete scaffold apposition at
baseline or 6 months demonstrated complete resolu-
tion of incomplete scaffold apposition at 2 years and
complete strut bioresorption at 5 years.
QUANTIFICATION OF SIGNAL-RICH LAYER. Median
values (IQR) for mean, minimum, and maximum
signal-rich layer thickness and symmetry were 330
mm (290 to 378 mm), 150 mm (120 to 190 mm), 570 mm
(500 to 640 mm), and 0.26 (0.20 to 0.33), respectively.
FIGURE 3 Plaque Characterization and Cap Tracing
In frames with necrotic core, calciﬁcations, or mixed plaque within the scaffolded segment, the overlying ﬁbrous cap was segmented and
minimum thicknesses were recorded. A spread-out map was generated that showed the component distribution within the neoplaque, with
lighter colors corresponding to thicker caps. Arrowhead indicates scaffold marker. GW ¼ guidewire.
FIGURE 2 Quantifying Signal-Rich Layer Thickness in Different Plaque Types
In the absence of attenuating intimal regions, the contour is traced at the internal elastic lamina (A). In plaques with necrotic core, the
abluminal contour is traced at the attenuating region boundary (B). In plaques with calciﬁcations, the signal-rich layer is segmented at the
calciﬁcation edge (C). Ca ¼ calcium; GW ¼ guidewire; NC ¼ necrotic core.
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FIGURE 4 Example of Attenuation Analysis
In all frames, tissue attenuation properties within adluminal and abluminal contour were measured and displayed on a color scale (blue represents low-attenuation
regions, whereas red and yellow represent high-attenuation regions). Analysis was performed in the signal-rich layer (A, B), as deﬁned in Figure 2, and in the entire
neoplaque, up to the internal elastic lamina (C, D). Note the lack of highly attenuating regions within the signal-rich layer (A, B), whereas attenuation properties deeper
in the neoplaque depended on tissue type (high attenuation in necrotic core; C). For intimal thickness <200 mm, as in 6 to 7 o’clock in A and C and 8 to 9 o’clock in
B and D, analysis was not performed because of lack of a sufﬁcient imaging window. Abbreviations as in Figure 2.
FIGURE 5 Different Types of Tissue Bridges Overlying Side Branches
Classiﬁcation was based on the relative location with the side-branch ostium. Four different types could be identiﬁed: proximal, distal, proximal
and distal, or crossing. Dotted lines indicate side-branch ostia; arrowhead indicates tissue bridge.
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FIGURE 6 Side-Branch Ostium Area Measurement by Cut-Plane Analysis
After 3-dimensional rendering, side-branch ostium area could be measured in a cut plane perpendicular to the side-branch ostium: L-mode
display (A); cross-sectional image (B); 3-dimensional rendering (C); derived perpendicular cut plane (D).
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of these thickness measurements.
NEOPLAQUE CHARACTERIZATION. Figure 8 pre-
sents spread-out neoplaque maps. The mean value of
minimum cap thickness was 310  113 mm, whereas
the minimum value was 155  90 mm. Mean and
maximum values were 92  49 and 156  72 for
necrotic core arc, 80 and 104 for calciﬁcation arc,
and 104  145 and 146  80 for mixed-plaque arc.
Microchannels were identiﬁed in 7 of 8 patients
and in 66 of 468 frames (14.1%). Per the neoplaque
maps, necrotic core or mixed plaque >1 quadrant was
observed in 7 patients. Comparison with previous
follow-ups did not reveal evidence of de novo
necrotic core accumulation of adluminal origin.
Two patients had a focally irregular lumen contour.
Patient #8 had a short intimal dissection, not present
at earlier investigations, at the overlap between
BVS and a metallic stent implanted at baseline. This
minor, angiographically not visible dissection was
most likely iatrogenic, induced by the guidewire. In
Patient #4, a thin-cap ﬁbroatheroma was observed at
the distal scaffold segment with cap disruption and
small thrombus (Figure 9). Post-hoc revision of pre-
vious OCT examinations revealed possible scaffold
discontinuity near the distal edge at 4 months,
with the scaffold being dislocated opposite to the
rupture site.ATTENUATION ANALYSIS. Mean per-patient attenu-
ation within the signal-rich layer was 1.77  0.32
mm1, and the median was 1.28  0.25 mm1
(Online Figure 3). This value was higher within the
entire neoplaque (mean per patient 2.87  0.54 mm1;
median per patient 2.33  0.49 mm1; p < 0.001)
(Online Figure 4). Spread-out attenuation maps at
different depths from the luminal surface are dis-
played in Figure 10. The surface layers (ﬁrst 200 mm)
had low attenuation, overlying high-attenuation
areas located deeper in the plaque.
SB ASSESSMENT. All SBs were patent with TIMI
(Thrombolysis In Myocardial Infarction) ﬂow grade 3.
Overall, 14 SBs were associated with incompletely
apposed struts at previous examinations. Neointimal
bridges at 5 years were identiﬁed in 13 SBs, whereas
in 1, no bridge was visible (Table 1).
Minimal and mean thickness of neointimal
bridges overlying SBs were respectively reduced
from 241  92 mm and 341  106 mm at 2 years to
161  107 mm and 227  119 mm at 5 years (p < 0.001)
(Online Figure 5).
METAL DRUG-ELUTING STENT ANALYSIS. Metal
drug-eluting stent (DES) analysis is presented in
Online Table 1 and Figure 11. In all metal stents,
coverage was >95%, without malapposed struts,
whereas neoatherosclerosis was identiﬁed in all.
FIGURE 7 Serial Luminal Measurements
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Despite an initial decrease in lumen dimensions from baseline to 6 months, minimal (A) and
mean (B) lumen areas were increased at 5 years compared with previous follow-ups and
were not signiﬁcantly different from baseline.
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2349VARIABILITY ANALYSIS. Interobserver and intra-
observer variability for both frame- and patient-level
analysis was low (interobserver: difference 0.23 
0.29 mm, ICC ¼ 0.98; interobserver [core laboratory]:
difference 0.13  0.32 mm, ICC ¼ 0.98; intraobserver:
difference 0.17  0.19 mm, ICC ¼ 0.99) (Online
Table 2, Online Figure 6). As seen in the Bland-
Altman plots, there were few measurements with
signiﬁcant differences, all of which were in the
polygon of conﬂuence of larger SBs with complex
geometry lacking a priori deﬁnitions for contour
tracing. ICCs for mean and minimal signal-rich layer
thickness were respectively 0.95 and 0.86 for intra-
observer variability and 0.80 and 0.80 for interob-
server variability.
DISCUSSION
We present the ﬁrst in vivo long-term OCT data after
BVS implantation. Despite the small sample size,
these ﬁrst patients treated with BVS offer a unique
opportunity to study the long-term vascular
response after BVS implantation (Figure 12). Our
main ﬁndings are that 5 years after BVS 1.0 implan-
tation: 1) there is late lumen enlargement with
simultaneous increase in luminal symmetry; 2) all
struts have disappeared and have been integrated
within the neointima and underlying plaque, form-
ing a homogeneous, signal-rich, low-attenuating
layer; 3) this signal-rich layer separates the lumen
from the underlying plaque with a minimum thick-
ness of 150 mm (IQR: 120 to 190 mm); 4) this effect is
not universal, with 1 case showing thinning and
disruption of the signal-rich layer; 5) jailed SB ostia
are preserved, whereas SB-related struts have been
replaced by thin tissue bridges; and 6) metal DES in
the same vessels are lacking a distinct signal-rich
layer and show neoatherosclerosis despite good
coverage and apposition (Central Illustration).
In our series, we observed a consistent luminal
enlargement from 2 to 5 years in all patients. Late
luminal enlargement in bioresorbable scaffolds has
been attributed to outward remodeling in animal
studies (14) and plaque burden reduction in clinical
trials (4,15). Our ﬁndings echo larger-scale intravas-
cular ultrasound (IVUS) observations of lumen area
increases from 6 months to 2 years after BVS im-
plantation (2,15). IVUS observations in our study
population were consistent with our ﬁndings, dis-
playing a trend for further lumen enlargement from 2
to 5 years, driven by a persistent decrease in plaque
size from 6 months to 2 years caused by either true
plaque regression or pseudoregression from strut
resorption (2,4). A similar trend was observed in the5-year multislice computed tomography follow-up of
ABSORB A (3). We observed recovery of luminal
symmetry, a ﬁnding of unclear signiﬁcance. Simul-
taneous observations of strut bioresorption and
signal-rich layer development suggest a potentially
favorable biological effect, which parallels IVUS
studies showing increased plaque rupture in eccentric
vessels (16). The observed complete strut bio-
resorption tracks with vasomotion ﬁndings demon-
strating a lack of mechanical vessel constraint, with
positive acetylcholine response in 4 patients, nega-
tive response in 2 patients, and absence of signiﬁcant
change in 2 patients (4).
FIGURE 8 Neoplaque Morphology
Spread-out maps from all patients demonstrating neoplaque composition. Red represents necrotic core; orange, mixed plaque; and white,
calciﬁcation. Lighter colors indicate a thicker ﬁbrous cap (>250 mm). The minimum and mean values of minimum cap thickness per patient are
presented in white and yellow, respectively.
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BVS resorption could serve as a mechanical barrier
that prevents potentially thrombogenic plaque com-
ponents from reaching the bloodstream, a concept
dubbed “plaque sealing” or “recapping the plaque”
(5,6). With this hypothesis in mind, we scrutinized
BVS morphology in our cohort, using sophisticated
algorithms for in-depth analysis. We focused on the
developed adluminal signal-rich layer, which corre-
sponds to neointima, bioresorbed struts, and ﬁbrous
components of the underlying plaque. The minimum
signal-rich layer thickness was 150 mm, and theminimum cap thickness over necrotic core was 155 
90 mm, bothwell beyond the 65-mmthreshold generally
accepted as high risk for plaque rupture (17), which
suggests that this layer could reliably separate the
lumen from potentially thrombogenic plaque compo-
nents. Importantly, this layer showed remarkable
homogeneity in the attenuation analysis, with low
attenuation values hinting at the absence of high-risk
wall components such as necrotic core and macro-
phages (9,10). This signal-rich layer could be protective
against very late scaffold thrombosis or de novo
thrombosis by plaque progression and rupture (1,17).
FIGURE 9 Vascular Response in Patient #4
At baseline, there was malapposition (white arrowheads) at the distal segment. At 106-
day follow-up, scaffold collapse (white arrowheads) at the site of the distal marker (white
bullet), overhanging struts (yellow arrowheads), and thrombus (yellow arrow) were
observed that suggested late scaffold discontinuity. At 6 months, a tissue bridge was
formed (white arrowheads) at the site of the collapsed scaffold and integrated into the
vascular wall by 24 months. Note the macrophage accumulation (white asterisks) at the
opposite side at 24 months. At 60-month follow-up, lesion progression with macrophages
and necrotic core was evident, as well as intimal disruption. At 72-month follow-up, there
was further luminal narrowing and plaque rupture with thrombus (white arrow). Black
arrows indicate scaffold markers. Abbreviations as in Figure 2.
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wall has shaped a neoplaque phenotype that resulted
from the complex interaction of pre-existing plaque,
morphological changes of the pre-existing plaque
subject to dynamic local rheological factors (18,19),
strut resorption, and neointima formation (8). We
visually characterized neoplaque using standardized
OCT criteria (7). Quantitative attenuation analysis
corroborated these qualitative ﬁndings, revealing
colocalization of necrotic core regions with high
attenuation regions (Online Figure 7), generally
located deeper in the vessel wall and rarely observed
within the ﬁrst 200 mm from luminal surface. Of note,
most patients were receiving intensive medical ther-
apy (statins, 75%; beta-blockers, 75%; angiotensin
receptor blockers, 62.5%), which possibly contributed
to this favorable phenotype.
Metal stents covered with well-organized and
functional neointima can likewise present a me-
chanical barrier between underlying plaque and
lumen. However, neointimal proliferation and neo-
atherosclerosis development over time have been
reported for bare-metal stents and are even more
accelerated for DES. The permanent nature of
the metallic structure further limits the vessel’s
capacity for remodeling, plaque regression, and
lumen enlargement over time. Consequently, lumen
narrowing develops inevitably over time, and indeed,
3 metal DES in our cohort showed adluminal neo-
atherosclerosis, with minimum cap thickness ranging
from 70 to 110 mm. This is notable because thin ﬁbrous
cap emerges as a risk factor for neointimal rupture
and acute coronary syndrome not only in native
atherosclerosis but also in neoatherosclerosis (1).
We analyzed the fate of SBs “jailed” by BVS, because
high strut thickness and tissue bridge formation have
raised questions regarding long-term patency (12).
Three-dimensional rendering demonstrated SB pa-
tency, allowed reliable ostial measurements, and
identiﬁed different intimal bridge patterns. Strut
integration into these tissue bridges was completed,
accompanied by bridge thinning from 341  106 mm at
2 years to 227  119 mm at 5 years. Together with the
angiographically conﬁrmed absence of ﬂow impair-
ment,we consider theseﬁndings a favorable long-term
outcome. However, the implications of BVS over large
SBs or in true bifurcation lesions remain unknown
(20,21), because these were excluded per protocol.
Overall, our long-term OCT observations suggest
a favorable vascular healing response with late
lumen enlargement, increased luminal symmetry, SB
patency, complete strut resorption, and formation
of a potentially protective tissue layer, giving an
appearance consistent with the hypothetical conceptof plaque sealing. Patient #4 did show a different
response, which captured our attention. We ob-
served target-lesion progression, with OCT ﬁndings
consistent with macrophage inﬁltration, abluminal
necrotic core accumulation, ﬁbrous cap thinning,
and plaque rupture at follow-up, while the pa-
tient was treated only with aspirin and clopidogrel.
This patient had diffuse disease that necessitated
non–target-lesion revascularization with a metal
FIGURE 10 Attenuation Spread-Out Maps
Spread-out maps demonstrating attenuation coefﬁcient in pre-deﬁned depths from the vessel surface (100, 200, and 400 mm) per patient. In
most patients, there was a low-attenuating layer of 200 mm separating the underlying plaque (starting at w400 mm) from the lumen. In
Patient #4, this layer was absent, and attenuating areas were close to the lumen.
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FIGURE 11 Representative Optical Coherence Tomography Images o
Covered struts (A, green bullet); neoatherosclerosis (B); distal edge ste
tinuity (D, white arrow); neoatherosclerosis (E); neointimal disruption (
evaginations-neointimal discontinuity (white arrow) possibly iatrogenic
Abbreviations as in Figure 2.
TABLE 1 Side-Branch Analysis
Bifurcation Type
SB Ostium
Area (mm2)
Jailing
Pattern
Patient #1: SB 1 OM-LCx 4.81 Proximal and distal
Patient #2: SB 1 LAD-septal 6.22 Crossing
Patient #2: SB 2 LAD-diagonal 1.14 Distal
Patient #2: SB 3 LAD-septal 1.89 Proximal
Patient #3: SB 1 LAD-diagonal 1.58 Distal
Patient #3: SB 2 LAD-septal 1.42 N/A*
Patient #4: SB 1 LCx-OM 1.11 Proximal and distal
Patient #5: SB 1 LAD-septal 1.93 Crossing
Patient #5: SB 2 LAD-diagonal 0.46 Distal
Patient #6: SB 1 LCx-OM 1.37 Crossing
Patient #6: SB 2 OM-LCx 2.23 Distal
Patient #8: SB 1 LCx-OM N/A† Proximal
Patient #8: SB 2 LCx–posterolateral 0.3 Proximal
Patient #8: SB 3 LCx-OM 0.78 Proximal
*The bridge was not present at 5 years; distal location at previous studies. †Exact
area not measurable.
LAD ¼ left anterior descending coronary artery; LCx ¼ left circumﬂex coronary
artery; N/A ¼ not available; OM ¼ obtuse marginal branch; SB ¼ side branch.
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2353paclitaxel-eluting stent in the same artery 106 days
after BVS implantation. This stent developed subse-
quent neoatherosclerosis with neointimal disruption
and microthrombus formation (Figure 11). This evi-
dence of accelerated atherosclerosis, combined with
mechanical factors (baseline incomplete scaffold
apposition followed by late structural discontinuity),
might have contributed to the adverse neoplaque
phenotype. Notably, the patient did not have a
clinically apparent acute coronary syndrome regard-
less of these impressive ﬁndings.
Despite the limited scale of our study, it provides
crucial information on the long-term vascular
response 5 years after BVS implantation. Although we
consider the overall vascular response to be favorable
and in line with larger-scale clinical reports, there
might be lessons to learn from observations in the
single patient who showed a different biological re-
action, with recurring plaque rupture after BVS im-
plantation. This ﬁnding might underscore the needf Metal Drug-Eluting Stents
nosis (C) (area ¼ 1.74 mm2); heterogeneous neointima with discon-
yellow arrow) over necrotic core with mural micro-thrombi (F);
(G); uncovered strut (H, red bullet); neoatherosclerosis (I).
FIGURE 12 Serial Assessment of Vascular Response
Matched representative images from serial examinations of all patients. Note the complete strut integration at 5 years, together with lumen enlargement, compared with
6-month and 2-year follow-ups. In Patient #8, intimal discontinuity (arrow), presumably iatrogenic, was observed. Green bullets indicate metal struts; white bullets
indicate scaffold markers. SB ¼ side branch; other abbreviations as in Figure 2.
CENTRAL ILLUSTRATION Long-term Vascular Healing in Bioresorbable Scaffolds
Karanasos, A. et al. J Am Coll Cardiol. 2014; 64(22):2343–56.
At long-term follow-up, bioresorbable vascular scaffolds (BVS) disappear, leaving behind late luminal enlargement, side-branch patency, and
a signal-rich, low-attenuating tissue layer that covers the thrombogenic plaque components.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Strut resorption
and vascular healing after bioresorbable vascular scaffold
implantation are associated with late lumen enlargement,
increased lumen symmetry, side-branch patency, and formation
of a potentially protective tissue layer over the long term.
COMPETENCY IN PATIENT CARE: Occasional observations
of unfavorable healing response after bioresorbable scaffold
implantation suggest a need for both optimum lesion coverage
and continued secondary prevention strategies after deployment
of bioresorbable vascular scaffolds.
TRANSLATIONAL OUTLOOK: Additional long-term follow-
up studies are needed to more completely characterize the
patterns of biodegradation associated with favorable and unfa-
vorable changes in plaque morphology and clinical outcomes
after implantation of bioresorbable vascular scaffolds.
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2355for an optimal acute mechanical result with optimal
lesion coverage, while simultaneously raising ques-
tions regarding a possible responder/nonresponder
reaction to BVS and the need for intensiﬁed second-
ary prevention in selected patients (22). As such, our
ﬁndings might guide further research for optimizing
the clinical efﬁcacy of BVS in light of the 1.1 version
modiﬁcations and herald observations in more com-
plex populations (23).
STUDY LIMITATIONS. This is a small ﬁrst-in-man
study, so selection bias cannot be excluded,
although the baseline clinical and angiographic
characteristics were not different from the entire
ABSORB A cohort. The BVS 1.0 assessed in our study
differs in geometry and resorption rate from the
currently used BVS 1.1, which might affect the tem-
poral course and pattern of the healing response.
Attenuation analysis has only been validated in
ex vivo specimens of native atherosclerosis and not
in device-induced tissue responses. However, be-
cause attenuation is an optical property of tissue
components, we expect the absence of high-
attenuating regions to correspond to absence of
necrotic core or macrophages in this setting.
Five-year OCT follow-up was performed with a
nonocclusive frequency-domain system; previous
OCT examinations were performed with an occlusive
time-domain system. Frequency-domain OCT offers
better image quality and higher dynamic range, which
allows superior visualization of deeply located plaques
(24). Because of these limitations of time-domain sys-
tems, serial assessment of plaque morphology was not
performed systematically andwas only examinedwith
reference to possible neoatherosclerosis, although
changes over time would be expected (19). Occlusive
time-domain OCT slightly underestimates lumen area
(25). Nevertheless, 4 patients in our study underwent
additional nonocclusive OCT imaging at 2-year follow-
up. When we compared nonocclusive data at 2 and
5 years, ﬁndings of late lumen enlargement were
consistent, albeit not reaching signiﬁcance because
of the smaller sample size (minimum lumen area
3.54  1.43 mm2 at 2 years vs. 4.06  1.33 mm2 at
5 years; p ¼ 0.14; mean lumen area 5.12  1.62 mm2
at 2 years vs. 5.95  1.20 mm2 at 5 years; p ¼ 0.07).CONCLUSIONS
At long-term follow-up 5 years after BVS implantation,
we observed a favorable tissue response with late
luminal enlargement, complete strut bioresorption,
and development of a low-attenuating, signal-rich
layer that covered the underlying potentially throm-
bogenic plaque components. The small scale of our
study and the observation of a different tissue re-
sponse in 1 patient warrant judicious interpretation of
our results and further conﬁrmation in larger studies.
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